Where to buy Argireline.

Argireline is the rare research peptide that also lives on drugstore shelves — the same molecule sits in over-the-counter serums and in lyophilized research vials, and the two supply chains behind those products are nothing alike. Where to buy Argireline in 2026 turns on which of those chains you're actually shopping: an INCI-listed cosmetic raw material sold by the kilogram in dilute carrier solutions, or a research-grade reference compound sold by the milligram with a per-lot Certificate of Analysis. Confusing the two is the single most common Argireline sourcing mistake.

Get new research first

Research updates

Citation-anchored summaries New-batch COA alerts Unsubscribe anytime

One short email when new peptide research drops or a new ISO 17025-verified batch lands — written from primary sources, no filler.

Subscribe

• CoA. Certificate of Analysis. A one-page lab report showing the specific lot's purity, identity, and net peptide content.
• ISO/IEC 17025. The international quality standard for testing labs. A 17025-accredited lab has been audited by a third party for technical competence.
• INCI. International Nomenclature of Cosmetic Ingredients. The naming registry for cosmetic raw materials — Argireline is listed as acetyl hexapeptide-8 (formerly acetyl hexapeptide-3).
• Lyophilized. Freeze-dried into a stable powder. Lyophilized peptides survive shipping at room temperature for short periods and store for years frozen.
• HPLC. High-performance liquid chromatography. The standard purity test for peptides. The chromatogram is the squiggly line that shows how clean the batch is.

What you're actually buying

Argireline is the trade name for acetyl hexapeptide-3, also registered under the newer INCI name acetyl hexapeptide-8. Both names refer to one molecule: a six-residue synthetic peptide, sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂, molecular formula C₃₄H₆₀N₁₄O₁₂S, molecular weight 889.0 g/mol. It was developed in the early 2000s by the Spanish biotech firm Lipotec — subsequently acquired by Lubrizol — and introduced as a topical anti-wrinkle cosmetic ingredient.

The design rationale was to mimic the N-terminal binding domain of SNAP-25, the SNARE-complex protein that botulinum toxin cleaves enzymatically. The short peptide competitively interferes with SNARE assembly and reduces acetylcholine release — reversibly and concentration-dependently, without the toxin's irreversible enzymatic cleavage (Blanes-Mira et al., 2002; Megighian et al., 2015). That mechanism is the entire basis of the “topical Botox” marketing — and the honest version of the story is narrower than the marketing. The strongest independent controlled trial, a vehicle-controlled study in 60 subjects, reported roughly 16% wrinkle-parameter improvement over an 84-day protocol at 10% topical concentration (Wang et al., 2013). Real, statistically detectable, and nowhere near the 60–80%+ bracket reported for injectable botulinum toxin at treated sites. The full evidence picture is in our complete Argireline research guide.

The other honest limitation is delivery. The 500 Dalton rule bounds passive skin penetration for compounds substantially above 500 Da (Bos & Meinardi, 2000). Argireline weighs 889 Da — well above the threshold — so the delivery vehicle, not the pharmacology, is the binding constraint on what topical formulations achieve. A hyaluronic-acid microneedle patch that physically bypasses the stratum corneum produced roughly 27% wrinkle-parameter reduction at 8 weeks, meaningfully more than topical-serum delivery (An et al., 2019). For a research buyer, that split matters: the compound's identity is the same in every format, but the published effect sizes are delivery-dependent.

The three places people buy Argireline

Because Argireline is a cosmetic ingredient with an industrial supply chain, it's available through three channels that look superficially similar and are not.

1. Research-supply vendors (the channel this guide is about)

Research vendors sell Argireline as lyophilized peptide powder, measured in milligrams, labeled “for laboratory research use only,” with a per-lot Certificate of Analysis. This is the only channel where the peptide's identity, purity, and quantity are independently verifiable by the buyer: the CoA states mass-spec identity, HPLC purity with the chromatogram, and net peptide content in mg.

Documentation to verify: a third-party CoA from an ISO 17025-accredited testing lab named on the report, mass-spec mass near 890.0 ([M+H]⁺), CAS 616204-22-9 on the identity line, and the mg-per-vial figure stated as tested rather than nominal.

2. The cosmetic raw-material (INCI) channel

This is the supply chain the molecule was actually built for. Lubrizol and other ingredient houses sell acetyl hexapeptide-8 to cosmetic formulators as a bulk raw material — typically pre-dissolved in a water/carrier solution, priced per kilogram of solution, and documented with a cosmetic-ingredient specification sheet (INCI name, preservative system, recommended use level) rather than a per-lot identity CoA. It's a legitimate, professionally run industrial channel. It is also a different product: percentage figures in this channel conventionally describe the stock solution, not peptide mass, and the actual peptide fraction of the liquid can be a small percentage of what the label number naively suggests.

The problem for research buyers isn't that this channel is illegitimate — it's that gray-market resellers repackage dilute cosmetic-grade solution into small vials and sell it alongside research-grade powder at research-grade prices. Without a CoA stating mg of peptide, the buyer has no way to know which product they received.

3. Finished cosmetics (serums and creams)

Argireline's retail life. Finished serums and creams at 5–10% formulation concentration are sold over the counter under cosmetic claims — that's the regulatory lane the ingredient was designed for, and it's the only channel where no research framing applies at all. A finished cosmetic is not research material: the peptide content is almost never disclosed in mg, the formulation matrix is proprietary, and no identity verification is possible. Relevant to consumers; not relevant to a lab sourcing a reference compound.

The Argireline-specific checks

The standard eight criteria for any peptide vendor apply. Four are sharper for Argireline specifically.

1. One molecule, two INCI names

Acetyl hexapeptide-3 and acetyl hexapeptide-8 are the same compound — the INCI registry shifted the designation, the sequence never changed. A vendor listing the two names as separate products, at separate prices, either doesn't understand its own catalog or is padding it. The CAS Registry Number 616204-22-9 is the unambiguous identifier and should appear on the CoA regardless of which trade or INCI name the label uses.

2. Acetylation and amidation identity

Argireline is capped at both ends: an acetyl group on the N-terminal glutamate and an amide on the C-terminal arginine. The acetyl cap alone adds 42 daltons. The uncapped hexapeptide is a different molecule — different mass (roughly 847 Da without the acetyl group), different stability, and not the compound validated in the published literature. Mass-spectrometry on the CoA should report the observed mass near 890.0 (the peptide picks up one hydrogen during the test, called [M+H]⁺), within about 0.5 daltons of target. A reading near 848 means the acetyl cap is missing. Any other significantly different mass means the vial does not contain Argireline.

3. Concentration and carrier verification

This is the check that separates Argireline from most research peptides. Because the cosmetic channel sells the molecule as a dilute solution, “percent” claims are ambiguous by convention: a “10% Argireline” label on a liquid product may describe 10% of a stock solution — not 10% peptide by mass. Research material should be lyophilized powder with peptide content stated in milligrams on the CoA, full stop. If a vendor sells Argireline as a liquid, the CoA must state the measured peptide concentration (mg/mL) and the carrier composition. A percentage with no mg figure anywhere in the documentation is not a specification — it's marketing.

4. The “topical Botox” claim check

The SNAP-25-mimetic mechanism is real and published: competitive, reversible interference with SNARE assembly, first characterized in chromaffin-cell models (Blanes-Mira et al., 2002). Botulinum toxin's mechanism is enzymatic and irreversible — it cleaves SNAP-25 rather than competing with it (Megighian et al., 2015). A vendor page that leans on “works like Botox” is blurring a competitive inhibitor into a proteolytic knockout, and blurring a ~10–27% published effect range into a 60–80%+ one. Vendors who describe the mechanism accurately tend to be the same vendors whose CoAs hold up.

Argireline

Hexapeptide 6 aa SNAP-25 mimic

The same acetylated, amidated hexapeptide characterized in the 2002 founding SNARE-inhibition study, the 2013 vehicle-controlled trial, and the 2019 microneedle-delivery study. CAS 616204-22-9, observed mass [M+H]⁺ near 890.0, ≥99% HPLC purity, ISO 17025 third-party CoA on every lot.

Shop Argireline →

2026 pricing benchmarks

Argireline is one of the cheapest peptides to synthesize on the research market: six residues, two simple caps, and an industrial-scale global supply chain built for the cosmetics industry. That supply-side reality keeps research-grade pricing low — and makes overpriced Argireline its own kind of red flag. ISO 17025-verified retail in 2026:

• 10 mg vial: $25–$55 ($2.50–$5.50/mg). The standard research size.
• 50 mg vial: $60–$110 ($1.20–$2.20/mg). Common for formulation-development work, where 5–10% w/w use levels consume material quickly.
• 100 mg+ and bulk: below $1.50/mg, trending toward cosmetic-ingredient economics. At this scale, verify the material is still lot-tested peptide powder, not repackaged ingredient solution.
• Multi-vial discounts: 10–25% off on 3-packs and 6-packs at most vendors.

Pricing meaningfully below $15 per 10 mg vial deserves a question — at that level the likeliest explanations are skipped HPLC purification, cosmetic-solution repackaging, or a nominal (untested) fill mass. Above roughly $8/mg, you're paying retail markup rather than synthesis cost: nothing about a six-residue peptide with an industrial supply chain justifies boutique pricing.

Legal status: cosmetic ingredient, not drug

Argireline occupies an unusual regulatory position for a peptide sold to researchers — it's one of the few with a fully legal consumer channel:

• United States (FDA): Not a drug. Regulated as a cosmetic ingredient; finished products are sold over the counter under cosmetic claims (“reduces the appearance of expression lines”). Raw peptide is sold legally as a research reference compound labeled for laboratory use only. Not a controlled substance.
• European Union: Cosmetic ingredient — Lubrizol INCI registration as acetyl hexapeptide-8.
• UK MHRA / Canada / Australia TGA: Cosmetic ingredient.
• WADA: Not listed; not a banned substance. (WADA Prohibited List for current categorizations.)

The boundary that matters is the claims boundary, not the substance. Cosmetic marketing may describe effects on the appearance of expression lines. Drug claims — treating a condition, paralyzing muscle, matching an injectable neuromodulator's clinical effect — move the product into drug territory regardless of the molecule's cosmetic status. A vendor making botulinum-equivalence claims has crossed that line, and it's the same vendors whose documentation tends to fall apart under the identity checks above.

Red flags specific to Argireline

• Percentage labels with no mg figure. The cosmetic channel's percent-of-solution convention makes “10% Argireline” ambiguous. Research material states peptide content in milligrams on a CoA. No mg number anywhere = not research-grade documentation.
• Pre-dissolved “research” liquid at powder prices. Dilute cosmetic-grade solution repackaged into small vials is the compound's characteristic gray-market move. Lyophilized powder is the verifiable format.
• Botulinum-equivalence claims. “Topical Botox,” “needle-free Botox results.” The published record shows ~10–27% wrinkle-parameter reductions depending on delivery format — not 60–80%+. Equivalence claims misrepresent both mechanism and magnitude.
• Acetyl hexapeptide-3 and -8 listed as different products. Same molecule, renamed in the INCI registry. Two listings at two prices is a catalog integrity failure.
• Mass-spec missing or not near 890.0 [M+H]⁺. A mass near 848 indicates the non-acetylated hexapeptide; any other significant mismatch means the wrong molecule entirely.
• Missing CAS 616204-22-9 on the CoA. The unique identifier that cuts through the trade-name/INCI-name tangle. Its absence is a documentation gap.
• Single-source documentation. Internal QC is not sufficient. Third-party ISO 17025 verification is the standard.

Argireline

10 mg ≥99% pure Lyophilized

Acetylated, amidated hexapeptide, CAS 616204-22-9, sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂. The same reference compound cited across the published SNARE-inhibition and cosmetic dermatology studies. ISO 17025-verified; COA with HPLC trace and mass-spec on every lot.

Learn more →

Frequently asked questions

Is Argireline legal to buy in the USA?

Yes. It's regulated as a cosmetic ingredient, not a drug — finished serums are sold over the counter, and the raw peptide is sold legally as a research reference compound labeled for laboratory use only. It's not FDA-approved as a drug for any indication and it's not a controlled substance. What's not legal is selling it under drug claims.

Are acetyl hexapeptide-3 and acetyl hexapeptide-8 the same compound?

Yes — one molecule, one sequence, two generations of INCI naming. The registry designation shifted from acetyl hexapeptide-3 to acetyl hexapeptide-8; the compound didn't change. CAS 616204-22-9 identifies it unambiguously under either name.

Is Argireline actually “topical Botox”?

No — the analogy is mechanistic shorthand, not equivalence. Both act on SNAP-25's role in the SNARE complex, but botulinum toxin cleaves the protein enzymatically and irreversibly, while Argireline competes with it reversibly (Megighian et al., 2015). Published controlled results run roughly 10–27% wrinkle-parameter reduction depending on delivery format, versus 60–80%+ for the injectable at treated sites.

What should an Argireline CoA show?

HPLC purity with the chromatogram, mass-spec identity near 890.0 ([M+H]⁺) for the 889.0 g/mol acetylated amidated hexapeptide, net peptide content in milligrams, water content by Karl Fischer titration, counterion content, and CAS 616204-22-9 on the identity line — from an ISO 17025-accredited lab named on the report.

What's the difference between a research vial and the cosmetic-ingredient version?

Format, documentation, and verifiability. Research-grade is lyophilized powder with a per-lot CoA stating identity and mg content. The cosmetic-ingredient channel sells the same INCI-listed molecule as a dilute bulk solution documented with a spec sheet, where percentage labels describe the solution rather than peptide mass. Both are legitimate in their own lanes; only one is verifiable as a reference compound.

Why does the delivery vehicle matter so much?

Because 889 Da sits well above the 500 Da passive-penetration threshold for intact skin (Bos & Meinardi, 2000). The published delivery gradient — ~16% for a topical serum in the controlled trial, ~27% when a microneedle patch bypasses the barrier — is the clearest natural experiment in the literature on how much the vehicle governs the outcome.

How does Argireline compare to GHK-Cu?

Different mechanisms, different wrinkle types, deeper literature for GHK-Cu. Argireline targets dynamic (expression-driven) lines via neuromuscular signaling; GHK-Cu targets static structural aging via collagen synthesis and dermal-matrix repair, with roughly five decades of academic data. The published formulation literature treats them as complementary rather than interchangeable.